Name: Cullinan Therapeutics, Inc. (CGEM) Financial Statements
Creator: FinSpry

Cullinan Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Cullinan Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.00	0.50	0.10	18.94	0.00
Cost of Revenue	0.31	0.00	0.00	0.00	0.00
Gross Profit	-0.31	0.50	0.10	18.94	0.00
Operating Expenses
Research & Development	142.90	148.16	91.95	57.75	43.21
Selling, General & Administrative	53.71	42.49	40.19	29.15	17.12
Operating Expenses	196.61	190.65	132.14	86.90	60.34
Operating Income	-196.92	-191.09	-132.14	-67.95	-60.34
Other Income/Expense
Interest Income	29.66	21.63	6.61	0.48	0.89
Interest Expense	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	29.46	-0.24	276.84	-0.01	-0.01
Income
Income Before Tax	-167.46	-169.22	151.32	-67.49	-59.46
Income Tax Expense	0.12	-14.12	42.12	0.00	0.00
Net Income	-167.38	-153.16	111.21	-65.57	-51.80
Net Income - Continuous Operations	-167.38	-155.10	109.20	-67.49	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-167.15	-179.07	-132.04	-67.90	-60.27
EBIT	-167.46	-169.22	-132.14	-67.95	-60.34
Depreciation & Amortization	0.31	0.30	0.09	0.05	0.06
Earnings Per Share
Basic EPS	-3.00	-4.00	2.00	-2.00	-3.00
Diluted EPS	-3.00	-4.00	2.00	-2.00	-3.00
Basic Shares Outstanding	53.77	41.55	45.16	43.08	19.89
Diluted Shares Outstanding	53.77	41.55	46.64	43.08	19.89